Oslo, Norway, March 6, 2023: Reference is made to Targovax ASA’s (“Targovax” or the “Company”) stock exchange announcement dated February 16, 2023, in which the Company will convene an Extraordinary General Meeting (EGM) at the Company’s offices raised at Lysaker on 9 March 2023 at 10:00 CET for the purpose of approving the investment agreement for up to NOK 300 million in convertible bonds with Atlas Special Opportunities, LLC (“Atlas”). A revised and redlined version of the Convertible Bond Terms and Section 5(x) of the EGM Invitation has been posted on the Company’s website: https://www.targovax.com/en/extraordinary-general-meeting-2023/ and is incorporated into this notice also attached. TRVX – EGM – Amended Section 5(x).pdf (https://mb.cision.com/Public/17093/3728354/9a2780ee1f064051.pdf) Redline – Updated Terms and Conditions – Convertible Senior Unsecured Bond Terms.pdf (https: // mb.cision.com/Public/17093/3728354/bdf5d6b0a25f570b.pdf) For further information please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: [email protected] Renate Birkeli , Investor Relations Phone: +47 922 61 624 Email: [email protected] Media Enquiries: Andreas Tinglum – Corporate Communications (Norway) Phone: +47 9300 1773 Email: [email protected] About Targovax Activation of the patient’s immune system to fight cancer Targovax (OSE: TRVX) is a clinical-stage immuno-oncology company developing immune activators that target hard-to-treat solid tumors. Targovax is focused on activating the patient’s immune system to fight cancer and helping cancer patients with few treatment alternatives available. Targovax is developing its product candidates in multiple cancer indications, including melanoma, mesothelioma, multiple myeloma and pancreatic cancer. Targovax’s lead clinical candidate, ONCOS-102, is a genetically engineered oncolytic adenovirus designed to selectively infect cancer cells and activate the immune system against the tumor. ONCOS-102 has demonstrated a favorable efficacy, immune and safety profile in multiple indications, both as monotherapy and in combination, and ONCOS-102 is in a randomized Phase 2 study in melanoma patients refractory to treatment with PD -1 checkpoint inhibitors are resistant. Targovax has also established a state-of-the-art circular RNA program (circRNA) with the intent to develop next-generation RNA therapeutics for various applications, building on clinical experience and deep mechanistic insights from its first-generation products. In addition, Targovax has a KRAS immunotherapy program with lead candidate TG01 set to enter clinical trials in early 2023 in an expanded format in pancreatic cancer and multiple myeloma. This provides Targovax with a rich pipeline of innovative future therapeutic candidates that will follow ONCOS-102.
Click here for more info
© Oslo Bors ASA, source Oslo Stock Exchange
